Usefulness of Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation and Complication Prediction in Oncological Patients Undergoing Colorectal Surgery

What this Trial Is About

Sarcopenia is a syndrome marked by progressive loss of muscle mass and strength, which negatively affects patients with cancer by worsening prognosis, increasing treatment side effects, and lowering quality of life. This study focuses on patients with gastrointestinal cancers, who are especially prone to sarcopenia due to the cancer itself and systemic anticancer treatments. Early detection of sarcopenia risk is crucial to provide timely nutritional and supportive care. Researchers will use the SARC-F questionnaire, a simple tool assessing muscle strength and function, to screen adult patients with gastrointestinal cancer before and during systemic anticancer therapy. Those who screen positive for sarcopenia risk will be referred for further clinical nutritional assessment and managed with individualized interventions by a multidisciplinary team. Treatment includes induction chemotherapy followed by chemoradiotherapy combined with cetuximab as per the study protocol. Participants will complete the SARC-F questionnaire at baseline and during treatment. Those at risk will undergo additional assessments such as body measurements and possibly DXA scans to evaluate muscle status more precisely. The study monitors outcomes including overall survival for up to five years, aiming to improve early identification and management of sarcopenia without adding extra diagnostic or therapeutic burden beyond standard care.

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery